Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in sickle cell disease: a phase 2, open-label study
Publication date
2022-07
Authors
van Dijk, Myrthe J
Rab, M A E
van Oirschot, Birgitte A
Eijkelenboom-Bos, Jennifer
Derichs, Cleo
Rijneveld, Anita W
Cnossen, Marjon H
Nur, Erfan
Biemond, Bart J
Bartels, Marije
Editors
Advisors
Supervisors
Document Type
Comment
Metadata
Show full item recordCollections
License
taverne
Abstract
Keywords
Taverne, Hematology, Letter
Citation
van Dijk, M J, Rab, M A E, van Oirschot, B A, Bos, J, Derichs, C, Rijneveld, A W, Cnossen, M H, Nur, E, Biemond, B J, Bartels, M, Jans, J J M, van Solinge, W W, Schutgens, R E G, van Wijk, R & van Beers, E J 2022, 'Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in sickle cell disease : a phase 2, open-label study', American Journal of Hematology, vol. 97, no. 7, pp. E226-E229. https://doi.org/10.1002/ajh.26554